We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Sponsor content
39 result(s) found, displaying 1 to 10
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for mRESVIA respiratory syncytial virus F protein mRNA (nucleoside modified), 50 micrograms in 0.5 mL, suspension for injection, prefilled syringe.
-
Jun-2025Prescription medicine evaluationActive ingredient: respiratory syncytial virus F protein mRNA (nucleoside modified).
-
Australian public assessment report (AusPar)mRESVIA is a vaccine that was approved for the prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV) in adults 60 years of age and older.
-
Prescription medicine registrationActive ingredients: respiratory syncytial virus F protein mRNA (nucleoside modified).
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for SPIKEVAX JN.1 (SARS-CoV-2 JN.1 mRNA) COVID-19 VACCINE 0.1 mg/mL suspension for injection pre-filled syringe.
-
Jan-2025Prescription medicine evaluationActive ingredient: SARS-CoV-2 spike NTD-RBD mRNA.
-
Cancellation by sponsorRequested by Moderna Australia Pty Ltd
-
Cancellation by sponsorRequested by Moderna Australia Pty Ltd
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for SPIKEVAX XBB.1.5 (andusomeran) COVID-19 VACCINE 0.1 mg/mL suspension for injection pre-filled syringe.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for SPIKEVAX XBB.1.5 (andusomeran) COVID-19 VACCINE 0.1 mg/mL suspension for injection vial - single-dose.